Skip to content

Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients

Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients Pre and Post Concurrent Chemo-radiation Therapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02854410
Enrollment
30
Registered
2016-08-03
Start date
2016-08-31
Completion date
2018-12-31
Last updated
2016-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma

Keywords

dietary sodium nitrate, radiotherapy, nasopharyngeal carcinoma

Brief summary

The purpose of this study is to evaluate whether dietary nitrate supplementation could improve the salivary flow for nasopharyngeal carcinoma patients receiving concurrent chemo-radiation therapy.

Detailed description

Thirty patients diagnosed as nasopharyngeal carcinoma will be recruited. Nitrate supplement(Sodium nitrate: 0.5 mmol/kgbodyweight,bid) or placebo(sodium chloride: 0.5 mmol/kgbodyweight,bid) will be provided to the patients from 7 days before radiotherapy to one month after the finish of radiotherapy . The salivary flow and plasma nitrate levels will be determined before the course of nitrate supplementation and radiotherapy,before the course of radiotherapy,post the course of radiotherapy immediately and one month after the finish of radiotherapy.

Interventions

DIETARY_SUPPLEMENTSodium nitrate

Dietary intake:Sodium nitrate 0.5mmol/kgbodyweight,bid

DIETARY_SUPPLEMENTsodium chloride

Dietary intake:sodium chloride 0.5mmol/kgbodyweight,bid

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
CollaboratorOTHER
Beijing Friendship Hospital
CollaboratorOTHER
Capital Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients with newly diagnosed stages III-IVb (UICC 2002) nasopharyngeal carcinomas, will be recruited.

Exclusion criteria

* Patients with local invasion or metastatic foci in salivary glands, detected by MRI and positron emission computed tomography(PET-CT) prior to treatment, were excluded, as were patients suffering from diseases, such as Sjogren's syndrome, or with a history of surgery to major salivary glands, or prior head and neck radiotherapy.

Design outcomes

Primary

MeasureTime frame
Change of salivary flowone day before the course of nitrate supplementation and radiotherapy,one day before the course of radiotherapy,one day post the course of radiotherapy and one month after the finish of radiotherapy

Secondary

MeasureTime frame
Chang of plasm nitrate levelone day before the course of nitrate supplementation and radiotherapy,one day before the course of radiotherapy,one day post the course of radiotherapy and one month after the finish of radiotherapy

Countries

China

Contacts

Primary ContactChang Shimin, PHD
changsm2005@163.com13520538923

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026